Tarsus Pharmaceuticals, Inc. Tarsus Pharmaceuticals, Inc.

Tarsus Pharmaceuticals, Inc.

TARS

Classement en actions #4648
Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm... Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to advancing and commercializing innovative therapies, primarily focusing on ocular conditions. Its leading investigational drug, TP-03, a novel treatment currently in Phase III trials, is being developed to address blepharitis specifically caused by Demodex mite infestations, as well as meibomian gland disease. Beyond this, Tarsus is also progressing TP-04 for rosacea and TP-05, which targets Lyme disease prevention and aims to reduce community-level malaria. A core element of its development strategy involves lotilaner, a compound utilized to tackle a variety of human diseases across diverse therapeutic areas, encompassing eye care, dermatology, and other medical fields. Established in 2016, the company maintains its headquarters in Irvine, California.
Prix de l'action
$69.50
Capitalisation boursière
$3.25B
Changement (1 jour)
0.00%
Changement (1 an)
-2.37%
Pays
US
Échange Tarsus Pharmaceuticals, Inc. (TARS)

Catégorie

Healthcare
Historique du rendement du dividende pour Tarsus Pharmaceuticals, Inc. (TARS)
Le rendement du dividende (TTM) de Tarsus Pharmaceuticals, Inc. (symbole boursier : TARS) au 2023-12-31 est : 0.00%
Rendement moyen du dividende sur les 5 dernières années : 0.00%
Historique du rendement du dividende de Tarsus Pharmaceuticals, Inc. (TARS) de 2018 à 2026
Rendement du dividende à la fin de chaque année (TTM)
Année Rendement du dividende Changez
2026 (TTM) 0.00% 0.00%
2024 0.00% 0.00%
2023 0.00% 0.00%
2022 0.00% 0.00%
2021 0.00% 0.00%
2020 0.00% 0.00%
2019 0.00% 0.00%
2018 0.00% 0.00%
Rendements du dividende (TTM) pour des entreprises similaires ou concurrentes
Entreprise Rendement du dividende Pays
0.00%
US
0.00%
US
2.17%
AU
0.00%
CH
0.00%
NL